One of the most common viruses in the world, an infection that the vast majority of people carry for life without ever thinking about it, has emerged as a leading suspect in the development of multiple sclerosis. Researchers now regard the Epstein-Barr virus not merely as a risk factor for the disabling neurological disease but as a likely necessary trigger, a shift in understanding that could eventually reshape how doctors think about prevention. The link does not mean that catching the virus leads to multiple sclerosis; nearly everyone is infected, yet only a tiny fraction ever develops the condition.
Epstein-Barr is the virus best known for causing infectious mononucleosis, the so-called kissing disease that spreads through saliva. Most people encounter it in childhood or adolescence, often with mild or unnoticeable symptoms, and it then settles into a lifelong dormant state in the body’s immune cells. That near-universal footprint is exactly what has made its connection to multiple sclerosis so intriguing and so difficult to untangle.
What multiple sclerosis does to the body
Multiple sclerosis is a disease of the central nervous system in which the immune system attacks myelin, the fatty insulating sheath that wraps around nerve fibers and allows electrical signals to travel quickly through the brain and spinal cord. As myelin is stripped away and scar tissue forms, communication between the nervous system and the rest of the body breaks down. The result can be a wide range of symptoms, from vision problems and numbness to muscle weakness, fatigue, and difficulty with coordination and balance, as the national neurological institute describes in its overview of the disease.
The condition varies enormously from person to person. Some experience relapsing episodes followed by periods of recovery, while others face a more steadily progressive course. It is most often diagnosed in young adults, and it affects women more frequently than men. For decades, researchers have understood multiple sclerosis to arise from a tangle of genetic susceptibility and environmental exposures, but the specific spark that sets the immune system against myelin has remained elusive.
Why the virus is the leading suspect
The case against Epstein-Barr has been built over years of epidemiological research. Studies tracking large populations have found that people who go on to develop multiple sclerosis are almost universally infected with the virus beforehand, and that infection appears to precede the disease rather than follow it. The strength of that association, combined with the observation that multiple sclerosis is exceedingly rare in people who have never been infected, has led many researchers to describe Epstein-Barr as a necessary, though far from sufficient, condition for the disease.
“Necessary but not sufficient” is the key phrase. It means that the virus appears to be required for multiple sclerosis to develop, yet its presence alone comes nowhere close to causing it. Since the overwhelming majority of the global population carries Epstein-Barr and only a small number ever develop multiple sclerosis, other factors must combine with the infection to tip a person toward disease. Those additional ingredients are where much of the current research is focused.
How a common virus might turn dangerous
Scientists have proposed several mechanisms by which a dormant virus might help trigger an assault on the nervous system. One leading idea is molecular mimicry, in which proteins from the virus resemble proteins in myelin closely enough that immune cells trained to attack the virus mistakenly turn on the body’s own nerve coverings. Another line of thinking centers on the way Epstein-Barr permanently reprograms the immune cells it infects, potentially priming them to behave abnormally years later.
These mechanisms help explain the long delay between infection and disease. A person may acquire the virus in childhood and not develop multiple sclerosis until early adulthood, if at all. The gap suggests that the infection sets a stage rather than pulling a trigger directly, with genetics, other environmental exposures, and the slow evolution of the immune response all contributing over time before symptoms ever appear.
What the connection could mean for prevention
The practical hope embedded in this research is prevention. If Epstein-Barr is genuinely a necessary trigger, then blocking or controlling the virus could, in principle, prevent a large share of multiple sclerosis cases. That prospect has intensified interest in developing a vaccine against Epstein-Barr, an effort that could carry benefits beyond multiple sclerosis given the virus’s links to certain cancers and other conditions. Antiviral strategies aimed at the dormant infection are also under investigation.
Those possibilities remain in the research stage, and none should alarm the billions of people who carry the virus without consequence. The likelihood that any given infected person will develop multiple sclerosis stays very low, and infection with Epstein-Barr is, for almost everyone, a routine and harmless part of life. What has changed is the scientific framing: a virus once seen mainly as the cause of a passing bout of mono is now understood as a probable gateway to one of the most significant neurological diseases, and that reframing is guiding a new generation of efforts to understand, and perhaps one day head off, multiple sclerosis.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
